In an article published in the Journal of Neurosurgery website, the study results were posted on Neonc Technologies Holdings’ recent animal study looking at the efficacy of using the NEO100 formulation for treating CNS disease in the brain. Malignancies of the CNS are difficult to treat because the blood-brain barrier (BBB) prevents most therapeutics from […]
In an article published on the Oncotarget.com website, the use of transfemoral injection of NEO100 to provide entry for therapeutics into the brain is explored. The paper provides an overview of the existing issue with clinicians to try and find better ways to get pharma-therapeutics past the Blood-Brain Barrier (BBB) for patients struggling with CNS-based […]
Los Angeles, CA, April 18, 2023 – NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory board as a strategic advisor. Dr. Iyabo Tinubu-Karch The company’s scientific advisory board, now comprised of five global healthcare leaders, provides NeOnc management with valuable guidance and perspectives on […]
Los Angeles, CA, Chicago, IL, London, UK, April 4, 2023 – NeOnc Technologies Holdings Inc., a clinical-stage medical biotechnology company, announced that its CEO, Thomas Chen, MD, Ph.D., has received the Best in Medicine Award from the American Health Council (AHC). As a national collaboration for the advancement of healthcare, the AHC honors with this […]
Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors. AnovaOS™ platform to support efficient patient identification and enrolment. Program designed to build upon early success of NEO100 with IDH1 mutated brain tumors (high-grade gliomas) in adult patients. Los Angeles, […]
